Thompson Siegel & Walmsley LLC Sells 83,227 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Thompson Siegel & Walmsley LLC reduced its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 21.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 306,793 shares of the medical research company’s stock after selling 83,227 shares during the quarter. Bio-Rad Laboratories makes up about 1.5% of Thompson Siegel & Walmsley LLC’s holdings, making the stock its 11th largest position. Thompson Siegel & Walmsley LLC owned about 1.10% of Bio-Rad Laboratories worth $102,647,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. UMB Bank n.a. lifted its position in Bio-Rad Laboratories by 140.6% in the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Capital Advisors Ltd. LLC lifted its holdings in shares of Bio-Rad Laboratories by 193.8% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock valued at $26,000 after buying an additional 62 shares during the period. Gladius Capital Management LP bought a new position in Bio-Rad Laboratories in the third quarter worth approximately $32,000. EntryPoint Capital LLC bought a new position in shares of Bio-Rad Laboratories during the 1st quarter valued at approximately $51,000. Finally, Headlands Technologies LLC purchased a new position in shares of Bio-Rad Laboratories in the second quarter valued at about $51,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Insider Activity at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the sale, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. The trade was a 28.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP James Barry sold 623 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now directly owns 147 shares of the company’s stock, valued at $48,582.03. This trade represents a 80.91 % decrease in their position. The disclosure for this sale can be found here. 17.06% of the stock is owned by insiders.

Bio-Rad Laboratories Stock Performance

Shares of Bio-Rad Laboratories stock opened at $323.69 on Thursday. The company has a 50 day moving average of $340.30 and a 200 day moving average of $315.25. Bio-Rad Laboratories, Inc. has a 52-week low of $262.12 and a 52-week high of $387.99. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.85. The firm had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.33 EPS. On average, research analysts predict that Bio-Rad Laboratories, Inc. will post 9.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on BIO. Citigroup increased their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Royal Bank of Canada raised their price target on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. StockNews.com upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Finally, Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 target price for the company. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories has an average rating of “Moderate Buy” and a consensus price target of $391.80.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.